Johnson & Johnson (JNJ)

Johnson & Johnson and Albertsons Companies' stock have provided a pleasant hedge against market volatility, with the S&P 500 and Nasdaq remaining near correction territory.

Amidst the tariff chaos, we may get clues from one of the most defensive sectors of the market-healthcare stocks.

Trump orders multi-part executive order to lower drug prices, reduce Medicare costs. Includes guidance on Medicare drug prices, aligning payments with hospital acquisition costs, and investigating anti-competitive practices.

Johnson & Johnson (JNJ) reported upbeat Q1 results amid an exciting earnings season, with analysts noting impressive sales and guidance from the pharma giant.

Johnson & Johnson had more good than bad; investors should look at the entire report in context before deciding if JNJ stock is a good fit for their portfolios

Edgewell and Kenvue are under-the-radar consumer staples stocks poised to gain as the U.S. dollar declines. Learn why they may boost your income portfolio.

Johnson & Johnson raised its 2025 sales outlook and dividend, while Q1 results topped expectations driven by strong cancer drug performance.

Johnson & Johnson stock fell alongside the broader market, despite beating first-quarter calls and hiking its sales outlook.

The company said the updated guidance includes costs estimated to be incurred as part of Trump’s tariffs on certain imports into the U.S.

Multinational healthcare company Johnson & Johnson (NYSE:JNJ) reported Q1 CY2025 results beating Wall Street’s revenue expectations, with sales up 2.4% year on year to $21.89 billion. The company’s full-year revenue guidance of $92 billion at the midpoint came in 1.9% above analysts’ estimates. Its non-GAAP profit of $2.77 per share was 7.3% above analysts’ consensus estimates.

Johnson & Johnson's first-quarter results surpassed expectations with notable growth in sales and earnings.

U.S. stock futures were volatile on Tuesday following a two-day advance. Futures of major benchmark indices were mixed in premarket.

After two days of back-to-back gains in the spot market, U.S. stock futures had a choppy session Monday night as investors await several prominent companies' earnings reports this week.

Multinational healthcare company Johnson & Johnson (NYSE:JNJ) will be reporting results tomorrow before market open. Here’s what investors should know.

There are valid reasons for the market to remain focused on the tariffs issue since so much is happening in the broader economy.

Novartis commits $23 billion to expand U.S. manufacturing and R&D with 10 new facilities, aiming to produce all key U.S. medicines domestically and add thousands of jobs.